What we do Indegene Limited is a digital-first life sciences commercialization company enabling biopharma, biotech, and medical device firms to accelerate product launch and scale operations using healthcare expertise and technology. |
Founded in 1,998 |
Market share Recognized among Financial Times High-Growth Companies Asia-Pacific 2025 and Deloitte Technology Fast 50; market leader in AI-driven life sciences solutions. |
Problem solved Addresses challenges in healthcare commercialization by integrating AI, analytics, and domain expertise to enhance marketing effectiveness, regulatory compliance, and clinical trial efficiency. |
Top clients or who we serve Serves biopharmaceuticals, emerging biotech firms, and medical device companies worldwide; B2B focused with top global pharma clients. |
Key management Manish Gupta, Chairman, Executive Director and CEO; Suhas Prabhu, CFO; Dr. Sanjay Parikh, Executive Director. |
Our journey and innovations Founded in 1998; evolved from private to public company in 2022; multiple acquisitions including Encima Group and biotech marketing agencies; launched AI platforms like Invisage and Cortex. |
Where we operate Global presence with delivery centers in India, US, Europe (UK, Spain), and offices across North America and Asia-Pacific. |
Top products or what we offer Enterprise Commercial, Medical, and Clinical Solutions; AI-driven platforms Invisage and Cortex; marketing analytics; regulatory and medical writing solutions. |
Top brands Invisage (AI-enabled omnichannel marketing), Cortex (Generative AI platform), Medical Writing Platforms, Pharmacovigilance automation. |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Predominantly recurring revenue from long-term client engagements in commercial and medical solutions. |
Our industry position Recognized leader in AI-powered life sciences commercialization; strong foothold in North America and Europe with expanding client base. |
Financial highlights FY25 consolidated revenue ₹2839 crore; net profit ₹406 crore; recent IPO raised ₹1842 crore; strong growth with 30.8% YoY revenue increase in Q3 FY26. |
Geographical revenue split North America 70%, Europe 25%, India and Rest of World ~5%. |
Order book - |
Whats driving growth Increasing adoption of AI and digital transformation in life sciences, strategic acquisitions, expanding client base, and new product launches. |
Our future plans Expand AI-driven platforms, strengthen global delivery centers, grow European footprint, and pursue strategic acquisitions. |
Our green promise Committed to reducing greenhouse gas emissions by 33.6% by FY28; 67% renewable electricity usage; focus on sustainability initiatives. |
Our people and values 5400+ employees globally; culture emphasizes empathy, collaboration, innovation, continuous learning, and diversity with 46% women employees. |
Key challenges ahead Managing integration of acquisitions, retaining skilled talent amid attrition, and adapting to evolving AI regulations. |
Interesting facts First $100 million+ revenue quarter achieved in Q3 FY26; recognized repeatedly for GenAI leadership and best places to work in India. |
Risks and strategy Mitigates risks through diverse services, robust compliance, continuous innovation, strong client partnerships, and dynamic risk management framework. |
